Literature DB >> 113981

IgA and IgG antibodies against surface antigens of Pseudomonas aeruginosa in sputum and serum from patients with cystic fibrosis.

P O Schiøtz, N Høiby, H Permin, A Wiik.   

Abstract

Eleven cystic fibrosis (CF) patients chronically infected in the lungs with mucoid Pseudomonas aeruginosa and presenting multiple precipitins in serum against this bacterium (CF + P) and 10 CF patients without P. aeruginosa infection (CF-P) had their serum and sputum sol phase specimens examined for antibodies of the IgA and IgG classes against surface antigens of P. aeruginosa by means of an indirect immunofluorescence technique. Both the IgA and IgG antibody titres demonstrated in serum and sputum of the CF + P patients were significantly higher than in those of the CF-P patients (p less than 0.01). The titre of IgA antibodies in the sputum was higher than in serum in 3 cases indicating local pulmonary production of specific IgA antibodies. The role of the demonstrated antibodies in the local pulmonary immune defense mechanisms and the possible patogenesis of the pulmonary tissue damage in CF patients is discussed.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 113981

Source DB:  PubMed          Journal:  Acta Pathol Microbiol Scand C        ISSN: 0304-1328


  7 in total

1.  Serum IgA antibodies against Pseudomonas aeruginosa in cystic fibrosis.

Authors:  M M Brett; A T Ghoneim; J M Littlewood
Journal:  Arch Dis Child       Date:  1990-03       Impact factor: 3.791

Review 2.  Microbiology of cystic fibrosis lung infections: themes and issues.

Authors:  J R Govan; J W Nelson
Journal:  J R Soc Med       Date:  1993       Impact factor: 5.344

3.  Immunoglobulin A and immunoglobulin G antibody responses to alginates from Pseudomonas aeruginosa in patients with cystic fibrosis.

Authors:  S S Pedersen; F Espersen; N Høiby; T Jensen
Journal:  J Clin Microbiol       Date:  1990-04       Impact factor: 5.948

4.  Safety and immunogenicity of an oral inactivated whole-cell pseudomonas aeruginosa vaccine administered to healthy human subjects.

Authors:  Allan W Cripps; Keith Peek; Margaret Dunkley; Kevin Vento; Joanne K Marjason; Madonna E McIntyre; Phil Sizer; Duncan Croft; Lis Sedlak-Weinstein
Journal:  Infect Immun       Date:  2006-02       Impact factor: 3.441

5.  Diagnostic and prognostic value of serum antibodies against Pseudomonas aeruginosa in cystic fibrosis.

Authors:  M Kappler; A Kraxner; D Reinhardt; B Ganster; M Griese; T Lang
Journal:  Thorax       Date:  2006-01-31       Impact factor: 9.139

6.  Lung immunoglobulin A immunity dysregulation in cystic fibrosis.

Authors:  Amandine M Collin; Marylène Lecocq; Sabrina Noel; Bruno Detry; François M Carlier; Frank Aboubakar Nana; Caroline Bouzin; Teresinha Leal; Marjorie Vermeersch; Virginia De Rose; Lucile Regard; Clémence Martin; Pierre-Régis Burgel; Delphine Hoton; Stijn Verleden; Antoine Froidure; Charles Pilette; Sophie Gohy
Journal:  EBioMedicine       Date:  2020-09-11       Impact factor: 8.143

Review 7.  Immunoglobulin A Mucosal Immunity and Altered Respiratory Epithelium in Cystic Fibrosis.

Authors:  Sophie Gohy; Alexandra Moeremans; Charles Pilette; Amandine Collin
Journal:  Cells       Date:  2021-12-20       Impact factor: 6.600

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.